With every passing day, new discoveries are made that lend support to the increasing and important role biomarker analysis and tumor profiling play in personalized cancer care. Caris Life Sciences® is actively participating in research to advance the understanding of molecular science, further enabling the delivery of precision medicine.

2017 Gastrointestinal Cancers Symposium (ASCO-GI)

Molecular Variances Between Rectal and Left Sided Colon Cancers

Molecular characterization of squamous cell carcinoma of the anal canal (SCCA)


Characterization of Tumor Mutation Burden (TMB) in Gastrointestinal (GI) Cancers.

2016 San Antonio Breast Conference

Racial differences in the molecular landscape of breast cancer 
Programmed death 1 (PD-1) and PD-1 ligand (PD-L1) distribution in triple negative breast cancer TNBC
ESR1 mutations, ESR1 fusions and co-occurring alterations assessed in breast cancer tumors

2016 Society for Neuro-Oncology (SNO)

Medulloblastoma candidate pathways for novel treatment strategies
Novel targets in ependymal tumors
PD-1,PD-L1 and genomic expression profiling of meningiomas 

2016 American Society of Clinical Oncology (ASCO) Annual Meeting

Comparative molecular analyses of BRAF-V600E mutant tumors: Colorectal cancers (CRC) vs. melanomas
Comparative molecular analyses of colon versus rectal tumors
Ras family mutation patterns in a large cohort of CRCs
Comparative molecular analyses of esophageal cancer: Adenocarcinoma vs. squamous cell carcinomas and impact on outcome
Use of panomic assessment to reveal DNA repair alterations and to predict potential therapeutic response to taxane-platinum combination therapy in prostate cancer
Differences in the molecular landscape of cancer between African American (AA) and Caucasian (CC) cancer patients
Novel panomic validation of time to next treatment (TNT) as an effective surrogate outcome measure in 4,729 patients
Comparative molecular analyses of pancreatic cancer (PC): KRAS wild type vs. KRAS mutant tumors and primary tumors vs. distant metastases
Distribution of PD-L1 expression in diverse cancer types: Experience with over 10,000 cases 
Fusion analysis of solid tumors to reveal novel rearrangements in breast carcinomas
Tumor profiling of liver metastases (LM) from CRC, NSCLC, pancreatic (PC), breast (BC) and gastroesophageal (GE) tumors to reveal differences versus primary tumors including in cMET, MYC, CDK4, Her2, b-catenin and PD1

2016 American Association for Cancer Research  (AACR) 

Multiplatform molecular profiling of invasive lobular breast cancer 
Molecular and genomic characterization of SCLC 
Clinico-pathological and molecular features associated with TP53 mutation in 3457 molecularly-profiled colorectal cancers (CRCs) 
Frequent BRCA2 somatic mutations in colorectal cancer patients with mircrosatellite instability (MSI) 
Mutations on the homologous recombination pathway in 13 cancer types 
Expression of class III beta-tubulin (TUBB3) in 3580 colorectal cancers (CRCs) and correlation with clinico-pathological and molecular features
A rationale for treatment of colorectal cancer with mitomycin C and crizotinib 
Analysis of MET-amplified solid tumors using chromogenic in situ hybridization (CISH) 

2016 Society of Gynecologic Oncology (SGO)

Multiplatform tumor-profiling of 50 malignant Sertoli-Leydig cell tumors of the ovary reveals therapeutic 

2016 Gastrointestinal Cancers Symposium (ASCO-GI)

Molecular characterization of colorectal tumors in young patients compared with older patients and impact on outcome 

2016 Genitourinary Cancers Symposium (ASCO – GU)

Molecular profiling of non-urothelial bladder cancer: adenocarcinoma and squamous cell carcinoma